These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3076200)

  • 41. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 42. Weekly drug holiday in Parkinson disease.
    Goetz CG; Tanner CM; Nausieda PA
    Neurology; 1981 Nov; 31(11):1460-2. PubMed ID: 7031503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration.
    Quadri R; Comino I; Scarzella L; Cacioli P; Zanone MM; Pipieri A; Bergamasco B; Chiandussi L
    Funct Neurol; 2000; 15(2):81-6. PubMed ID: 10916719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [L-dopa and bromocriptine in Parkinson disease. Early combination therapy has better effect].
    Olsson JE; Duchek M; Ekberg R; Fehling C; Johansson F; Johnels B; Lindvall B; Nordin G; Sidén A; Steg G
    Lakartidningen; 1993 Apr; 90(16):1545-8. PubMed ID: 8483351
    [No Abstract]   [Full Text] [Related]  

  • 45. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
    Omoto T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
    [No Abstract]   [Full Text] [Related]  

  • 46. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

  • 47. [Treatment of complicated Parkinson disease with a solution of levodopa-carbidopa and ascorbic acid].
    Linazasoro G; Gorospe A
    Neurologia; 1995; 10(6):220-3. PubMed ID: 7546811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 49. [Experience with the use of parlodel in the treatment of Parkinson patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Pivovarova VM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):219-22. PubMed ID: 3705825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
    Shiozawa R; Kase M; Kuroiwa Y; Narabayashi H; Nishitani Y; Ohmoto T; Toyokura Y; Uono K
    No To Shinkei; 1981 Mar; 33(3):301-9. PubMed ID: 7018522
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A year of treatment with carbidopa and levodopa in Parkinsonian patients].
    Martínez-Lage JM; Marti-Massó JF; Delgado G; Carreray N; Del Amo F
    Rev Clin Esp; 1974 Sep; 134(6):535-42. PubMed ID: 4450036
    [No Abstract]   [Full Text] [Related]  

  • 53. Early combination of dopamine agonist and levodopa in the treatment of Parkinson's disease.
    Rinne UK
    Mt Sinai J Med; 1988 Mar; 55(2):138-41. PubMed ID: 3260342
    [No Abstract]   [Full Text] [Related]  

  • 54. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bromocriptine in parkinsonism. A long-term study.
    Lees AJ; Haddad S; Shaw KM; Kohout LJ; Stern GM
    Arch Neurol; 1978 Aug; 35(8):503-5. PubMed ID: 666607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Method of addition of bromocriptine to the drug regime of patients with advanced Parkinson's disease.
    Grimes JD; Hassan MN
    Can J Neurol Sci; 1981 Feb; 8(1):31-4. PubMed ID: 7225954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical significance of long-term treatment of L-dopa with bromocriptine in parkinsonian patients who showed declining efficacy during L-dopa therapy].
    Indo T
    Nihon Naika Gakkai Zasshi; 1985 Mar; 74(3):297-306. PubMed ID: 4009013
    [No Abstract]   [Full Text] [Related]  

  • 58. Ropinirole: new preparation. Wait for more convincing data.
    Prescrire Int; 1998 Apr; 7(34):36-8. PubMed ID: 10183378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
    Westin J; Nyholm D; Groth T; Dougherty MS; Yerramsetty PK; Palhagen SE
    Parkinsonism Relat Disord; 2006 Dec; 12(8):509-13. PubMed ID: 16731025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
    Factor SA
    Mov Disord; 1993 Apr; 8(2):240-1. PubMed ID: 8474504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.